A Phase 1 interventional study of BI 1015550 and BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-15.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this first-in-man trial, safety, tolerability, pharmacokinetics, and selected pharmacodynamics parameters of BI 1015550 will be assessed in healthy male volunteers.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 1015550
Powder for oral solution
Drug: BI 101550
Solution for oral administration
Drug: Placebo
High dose powder for oral solution
Medium dose powder for oral solution
Low dose powder for oral solution
Low dose powder for oral solution
Low dose powder for oral solution
Solution for oral administration
High dose powder for oral solution
Low dose powder for oral solution
Medium dose powder for oral solution
Medium dose powder for oral solution
Number (%) of Subjects With Drug Related Adverse Events
Percentage of subjects with drug related adverse events.
Time frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory Tests
Percentage of subjects with clinically relevant abnormalities in clinical laboratory tests (haematology, clinical chemistry, haemoccult® test, and urinalysis).
Time frame: Day -21 to -2, upto -72 hours, 4h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
Number (%) of Subjects With Clinically Relevant Abnormalities in Vital Signs
Percentage of subjects with clinically relevant abnormalities in vital signs (blood pressure, pulse rate, respiratory rate, oral body temperature, orthostasis test).
Time frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
Number (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGs
Percentage of subjects with clinically relevant abnormalities in 12-lead ECGs.
Time frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
Number (%) of Subjects With Clinically Relevant Abnormalities in Tolerability
Percentage of subjects with clinically relevant abnormalities in tolerability assessed by the investigator.
Time frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
Number (%) of Subjects With Clinically Relevant Abnormalities in Physical Examinations
Percentage of subjects with clinically relevant abnormalities in physical examinations.
Time frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
Cmax of BI 1015550
Maximum measured concentration of the analyte in plasma.
Time frame: -0.5hour before dosing and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing
AUC0-infinity of BI 1015550
Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity
Time frame: -0.5hour before dosing and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing
70 patients were treated and analysed.
| Milestone | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 16 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 16 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of subjects with drug related adverse events.
| Percentage of Participants | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) of Subjects With Drug Related Adverse Events | 0.0 | 33.3 | 16.7 | 0.0 | 0.0 | 33.3 | 16.7 | 16.7 | 16.7 | 6.3 |
Percentage of subjects with clinically relevant abnormalities in clinical laboratory tests (haematology, clinical chemistry, haemoccult® test, and urinalysis).
| Percentage of Participants | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory Tests | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Percentage of subjects with clinically relevant abnormalities in vital signs (blood pressure, pulse rate, respiratory rate, oral body temperature, orthostasis test).
| Percentage of Participants | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) of Subjects With Clinically Relevant Abnormalities in Vital Signs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Percentage of subjects with clinically relevant abnormalities in 12-lead ECGs.
| Percentage of Participants | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Percentage of subjects with clinically relevant abnormalities in tolerability assessed by the investigator.
| Percentage of Participants | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) of Subjects With Clinically Relevant Abnormalities in Tolerability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Percentage of subjects with clinically relevant abnormalities in physical examinations.
| Percentage of Participants | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) of Subjects With Clinically Relevant Abnormalities in Physical Examinations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Maximum measured concentration of the analyte in plasma.
| nmol/L | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg |
|---|---|---|---|---|---|---|---|---|---|
| Cmax of BI 1015550 | NA ± NA | 1.42 ± 23.2 | 5.02 ± 20.1 | 13.7 ± 14.2 | 46.9 ± 38.9 | 113 ± 20.4 | 176 ± 12.6 | 292 ± 22.2 | 542 ± 12.1 |
Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity
| nmol*h/L | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg |
|---|---|---|---|---|---|---|---|---|---|
| AUC0-infinity of BI 1015550 | NA ± NA | 7.44 ± 12.7 | 24.1 ± 13.9 | 67.9 ± 15.6 | 287 ± 14.9 | 679 ± 32.0 | 1210 ± 18.3 | 2180 ± 19.9 | 3650 ± 22.6 |
Collected over From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/16 (0%) | 5/16 (31.3%) |
| BI 1015550 Low Dose 0.02mg | — | 0/6 (0%) | 2/6 (33.3%) |
| BI 1015550 Low Dose 0.06mg | — | 0/6 (0%) | 2/6 (33.3%) |
| BI 1015550 Low Dose 0.2mg | — | 0/6 (0%) | 3/6 (50%) |
| BI 1015550 Low Dose 0.6mg | — | 0/6 (0%) | 3/6 (50%) |
| BI 1015550 Medium Dose 2mg | — | 0/6 (0%) | 1/6 (16.7%) |
| BI 1015550 Medium Dose 4mg | — | 0/6 (0%) | 3/6 (50%) |
| BI 1015550 Medium Dose 8mg | — | 0/6 (0%) | 3/6 (50%) |
| BI 1015550 High Dose 16mg | — | 0/6 (0%) | 2/6 (33.3%) |
| BI 1015550 High Dose 24mg | — | 0/6 (0%) | 3/6 (50%) |
| Event | Placebo | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/16 | 0/6 | 1/6 | 1/6 | 1/6 | 1/6 | 2/6 | 2/6 | 0/6 | 0/6 |
| Ear discomfortEar and labyrinth disorders | 0/16 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/16 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| Lip dryGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| NauseaGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Application site irritationGeneral disorders | 0/16 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 |
| FatigueGeneral disorders | 0/16 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Oral herpesInfections and infestations | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken at least 1 dose of the investigational treatment.
| Age, Continuous(Years) | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.5 ± 5.1 | 29.5 ± 4.8 | 38.2 ± 6.5 | 35.0 ± 5.5 | 35.5 ± 5.9 | 32.7 ± 5.9 | 36.3 ± 6.3 | 40.5 ± 3.3 | 33.5 ± 8.4 | 36.6 ± 5.6 | 35.3 ± 6.1 |
| Sex: Female, Male(Participants) | BI 1015550 Low Dose 0.02mg | BI 1015550 Low Dose 0.06mg | BI 1015550 Low Dose 0.2mg | BI 1015550 Low Dose 0.6mg | BI 1015550 Medium Dose 2mg | BI 1015550 Medium Dose 4mg | BI 1015550 Medium Dose 8mg | BI 1015550 High Dose 16mg | BI 1015550 High Dose 24mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 16 | 70 |
The record gives a start of May 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast